Upstate Active Clinical Trials

Study Title:

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD

What is the purpose of the study?

Treatment study to improve cure rate for AML by adding bortezomib, to the standard chemotherapy regimen, to find out the dose and effectiveness of sorafenib & to better understand the biology of AML better.